Pan-APAC Focus
Only fund with a devoted strategy to unlock carve- out opportunities across Pan-APAC pharma and medtech market
Carve-Out Specialist
Build on deep operational, regulatory, and transactional expertise across regional, business, and asset-level
Proprietary Access
Off-market visibility and deal origination via deep relationships with global and regional leaders at MNCs, built on our history of successful partnerships and transactions
Active Alpha Engine
Beyond capital, hands-on value creation via TOT (total operation transformation), commercial scaling, territorial expansion and add-on M&A/licensing
Exit-Driven Discipline
Engagement with source of liquidity at project onset and throughout the project life cycle; Strong bias toward structured exits via trade sales, IPOs, or strategic M&A
First-ever Pan-APAC Divestiture Fund with Active Alpha Value Creation
About PTG Capital
An Alterative Route to Build Market-leading Business while derisking capital deployment
Our Opportunity
- $2.7T APAC healthcare market by 2026, accounting for 40% of global healthcare growth by 2030
- Despite the above, APAC lacks impactful global or regional
pharma and medtech platforms - PE/VCs focus on biotech buildup – a traditionally sequential
way of “biotech to pharma” model - MNC (Multi-National Company) reorientation creating rich divestiture pipeline
- Effective hedge again US pricing pressure and regulatory headwind
Why Pan-APC?
Why Now?
Pan-APAC represents the world’s largest structural arbitrage in healthcare – and a timely hedge against U.S. price compression and regulatory headwinds.
Our Differentiation:
Acquiring, Building-on and Scaling
We are purpose-built to succeed where traditional PE approaches fall short in the APAC carve-out landscape. We deliver value beyond capital by leveraging proprietary access, domain expertise, operational transformation, and disciplined growth execution.
Our Solution
- Deep-rooted domain expertise to Identify and proprietary-source under-managed and -appreciated assets from MNCs
- Proven track record in leading complex carve-out transactions and/or syndicating deals with other prominent PE firms/strategic investors
- Activist operator-investor approach focused on TOT (total operational transformation) to accelerate value creation BD Expertise and network fuels business upscaling via bolt-On M&A and licensing
PTG Over 20 Years of Experience
With a combined experience of >25+ complex transactions over 20 years in the healthcare and finance industry, PTG Team brings a strong blend of Operational and Investment Expertise.
Years in the Industry
20+
transaction size
$2B+
dEAL COUNT
25+
cOVERED MNC number
30+
Deep network of Healthcare MNC Partners
With a proven track record of success, PTG Capital is trusted by top pharma and medtech companies.
